Since its launch, Brightwell has been involved in over $2.5bn of fundraisings, including Syncona, a collaboration between the Wellcome Trust, Cancer Research UK and the Battle Against Cancer Investment Trust to form a leading global investor in new medical technologies.
Brightwell has worked on the Dementia Discovery Fund (DDF) alongside SV Health Investors, an international venture capital firm focused on biotech and life sciences more generally. The DDF is a unique collaboration between government, charity and big pharma and aims to develop disease modifying drugs for dementia more broadly, including Alzheimer’s. The DDF is one of the largest early stage single strategy venture capital funds ever raised.
More recently Brightwell has helped SV Health Investors on the Impact Medicine Fund (IMF), a venture capital bio-tech fund focusing on developing precision therapies.
Going forward Brightwell’s focus will be the creation of products and the raising of funds around the UN’s Sustainable Development Goals (SDGs) with particular interest in climate change. Brightwell also redirects a share of its revenues to charitable causes and impact initiatives.